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Summary
Mutations in the gene encoding the phosphotyrosinephosphatase PTP1C, a cytoplasmic protein
containing a C0014-terminal catalytic and two NH2-terminal Src homology 2 (SH2) domains,
have been identified in motheaten (me) and viable motheaten (me) mice and are associated with
severe hemopoietic dysregulation. The me mutation is predicted to result in termination of the
PTP1C polypeptide within the first SH2 domain, whereas the me° mutation creates an insertion
or deletion in the phosphatase domain. No PTPIC RNA or protein could be detected in the
hemopoietic tissues ofme mice, nor couldPTP1C phosphotyrosine phosphatase activity be isolated
from cells homozygous for the me mutation. In contrast, mice homozygous for the less severe
me mutation expressed levels of full-length PTP1C protein comparable to those detected in wild
type mice and the SH2 domains of me° PTPIC bound normally to phosphotyrosine-containing
ligands in vitro. Nevertheless, the me mutation induced a marked reduction in PTPIC activity.
These observations provide strong evidence that the motheaten phenotypic results from loss-of-
function mutations in the PTP1C gene and imply a critical role for PTP1C in the regulation
of hemopoietic differentiation and immune function.
H omozygosity for the motheaten (me)' or allelic viable
motheaten (mev) mutations is associated with early
onset ofa severe autoimmune and immunodeficiency disease
that leads to deathby age 3 or 9 wk, respectively (1, 2) . The
disease reflects the presence of multiple hemopoietic cell ab-
normalities which include a marked overexpansion of the
autoantibody-secreting CD5 + subpopulation of peripheral
B cells (3), a paucity of both B cell progenitors in the bone
marrow and conventional B cells in the periphery (4), im-
paired T cell and NK cell function (5, 6), and increased produc-
tion and tissue accumulation of granulocytes and mono-
cyte/macrophages (2, 7). All ofthese defects can be transferred
by transplantation of me or me° bone marrow into irradiated
wild type mice (8, 9), suggesting that the me locus acts in
a cell autonomous manner to regulate a critical aspect of
hemopoietic cell proliferation and differentiation.
We have previously shown that me and me" mice have
mutations in a gene encoding PTPIC (10), an intracellular
1 Abbreviations usedin this paper. EGFR, epidermal growth factor receptor;
GST glutathione S-transferase; me, motheaten; mev, viable motheaten;
PDGF, platelet derived growth factor.
tyrosine phosphatase expressed predominantly in hemopoietic
cells and also known as HCP, SH-PTP1, and SHP (11-14).
PTP1C represents one of three cytoplasmic tyrosine phos-
phatases identified to date that contain two tandemly aligned
Src homology 2 (SH2) domains, and which may therefore
be involved in regulation oftyrosine kinase-mediated signaling
cascades (15-18). In contrast to the normal PTP1C transcript,
PTP1C mRNAs amplified by RT-PCR from me bone marrow
cells have a 101-base pair frame-shift deletion in the coding
region of the NH2-terminal SH2 domain, while those
amplified from me° bone marrow have either a 15-base pair
in-frame deletion or a 69-base pair in-frame insertion within
the sequence encoding the PTP1C catalytic domain (10). These
abnormalities were shown to ariseby virtue of altered mRNA
splicing in both the me and me PTPIC genes resulting from
single base pair mutations which alter splice signal sequences.
These genetic data have recently been confirmed by Shultz
et al. (19) and together with the recent localization of the
PTP1C gene to the vicinity of the me locus on mouse chro-
mosome 6 (19, 20), suggest that mutation of the PTPIC gene
underlies expression of the me and me, phenotype. To ex-
plore this possibility, PTPIC function and expression have
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The resultant data reveal that PTP1C tyrosine phosphatase
expression and catalytic activity are severely impaired in me
and me° mice and thus suggest strongly that the motheaten
phenotype is caused by loss-of-function mutations in the
PTP1C gene.
Materials and Methods
Mice.
￿
Mice forthese studieswere obtained by mating C57BL/6J
me°/+ and +/+ and C3HeBFeJ mel+ and +/+ breeding pairs
originally provided by TheJackson Laboratory (Bar Harbor, ME).
PCR-based Assays of PTP1C Mutation.
￿
To detect the me'
PTPIC gene T-A transversion, a 120-bp pair genomic fragment
encompassing thesite ofthemutation wasamplifiedfrom tail DNA
using the primers PTPlCl002-5'(5'-CAGGAGAACACTCGTG-
TCAT3') and PTPlC1122-3'(5'-TGTATGGTATTGAACAAGG-
ACC-3'), 2.5 U Taq polymerase (Pharmacia, Baie d'Urfe, Que.,
Canada), and thefollowingPCRconditions: 5 min 95°C,followed
by 30 cycles of 1.5 min at 94°C, 1 min 58°C, 1 min 72°C, and
7 min 72°C (last cycle). 5 p.l of PCR product were mixed with
5 pmol unlabeledprimer PTP1C1028 (5'-GACTACCAGAGAGGT
GGAGAAAGG-3') and 1.0 U Taq polymerase and subjected to 10
cycles of PCR primer extensionusing theinitial PCR conditions.
5 pl of extension product was then mixed with 5 pmol [y3Z-
P]dATP end-labeled PTP1C1028primer, 1.0 U Taqpolymerase, and
100p.M dCTP,dGTP, dTTP, and dATP and subjected to asecond
round of PCR primer extensions. 2 Al of final reaction mixture
was then electrophoresed over a 15% SDS-polyacrylamide gel at
80 Wfor 2 h, and the extension products visualized by autoradi-
ography. To detect the me PTP1C gene C nucleotide deletion, a
118-base pair genomic fragment encompassing the site of the mu-
tation was amplifiedfrom tail DNA usingtheprimers PTP1C175-
5'(5'-ACTTCTATGACCTGTACGGA-3') and PTPIC293-3'(5'TAC-
TTAAGGTGGATGATGGTGC-3'), 1.5 U Taqpolymerase, and the
PCR conditions described above. After TagI digestion and elec-
trophoresis at 150 V for 3 h on a 12% SDS-polyacrylamide gel,
PCR products were visualized by ethidium bromide staining.
RNA IsolationandAnalysis.
￿
Total cellular RNA wasextracted
from spleen, thymus,andbone marrow tissue obtained from normal
and mutant mice as previously described (21). ForNorthern anal-
ysis, 20 pg RNA samples were electrophoresed over 1% agarose-
formaldehyde gels, transferred to GeneScreen Plus membranes(New
England Nuclear, Mississauga, Ont., Canada), and hybridized with
a 1-kb PCRfragment amplifiedfrom the PTPIC transcript phos-
phatase region (10). Afterautoradiography, blotswere stripped and
rehybridized with a 300-base pair O-actin gene fragment.
GSTPTPIC Fusion Proteins.
￿
To generate glutathione S-trans-
ferase (GST)-PTPlCSH2 domain fusion proteins, DNAfragments
encompassing the two PTP1C SH2 domains (amino acids 1-296)
were PCR amplified from wild type-, me'- andme-derived PTP1C
cDNA template using oligonucleotide primers containing the ap-
propriate restriction sites and complementary to the sequences
flanking theSH2domain region (10). AfterEcoRI/BamHI diges-
tion,theamplifiedproducts werecloned into pGEX-2T(Pharmacia),
transformed into DH5ct Escherichia coli and the GST fusion pro-
teins were purified from bacterial lysates as previously described (22).
Antibodies.
￿
Polyclonal anti-PTPIC andanti-Syp antibodies were
generated by injecting rabbits with 100 pg wild type GSTPTP1C
SH2domain fusion protein or with aGSTfusion protein containing
the two SH2 domains (residues 2-216) of Syp as previously de-
scribed (16) .
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Immunoblotting Analysis.
￿
Totalcellular protein lysates were pre-
pared by resuspending freshly isolated bone marrow, spleen, or
thymic tissues in 1 ml lysis buffer (phosphate buffered saline, pH
7.0, containing 1% Triton X-100, 1% Tween, 1 mM sodium or-
thovanadate, 1pg/mlleupeptin, 1 jig/ml aprotinin, and0.001 mM
DTT). 100 jig of total cell lysate protein was electrophoresed
through 10% SDS-polyacrylamide, electroblotted onto nitrocellu-
lose membranes, and the proteins were detected by immunoblot-
ting with polyclonal rabbit anti-PTP1C SH2or anti-Sypantibodies
(1:1,000 dilution) followed by "'I-protein A as previously de-
scribed (23) .
PTPICImmunoprecipitation andPhosphataseActivity.
￿
100pg total
spleen or livercell lysate protein wasincubatedfor2 h at 4°C with
20 pl anti-PTP1C SH2 or anti-Syp SH2 antibodies, respectively,
and 100pl of protein A-Sepharose (Pharmacia). Immune complexes
were collectedby centrifugation (5 min 10,000 g) and onehalf of
each sample waswashed threetimeswith lysis buffer, pelleted, boiled
for 5 minin SDS-sample buffer, and electrophoresed over 10% poly-
acrylamide. After transfer to nitrocellulose, specific proteins were
detected by immunoblotting with theanti-PTP1C or anti-Syp an-
tibodies followed by 'z1I-protein A. For phosphatase assays, por-
tions of the anti-PTP1C and anti-Syp immunoprecipitates were
incubated in reaction buffer (24) at 37°C with 2mMp-nitrophenyl
phosphate (Sigma Chemical Co., St. Louis, MO). Reactionswere
terminated by addition of 1 ml 200 mM NaOH and absorbance
at 410 mM was determined.
In VitroBindingAssays.
￿
Forbindingassays, Rat-1 cells (RlhER)
overexpressing thehumanepidermal growth factor receptor (EGFR)
and Rat-2 fibroblasts were grown in Dulbecco's modified Eagle
medium supplemented with 10% FBS andthen serum-starvedfor
48 h. Quiescent R1bER and Rat-2cells were either left unstimu-
lated or stimulated for 5 min at 37°C with EGF (80 ng/ml) or
platelet derived growth factor (PDGF, 75 ng/ml),respectively (Up-
state Biotechnology, Inc., Lake Placid, NY). After lysis, aliquots
of thecell lysates were incubatedfor 1 h at 4°C with 5jigpurified
wild type, me or me GSTPTPIC SH2 domain fusion proteins im-
mobilized on glutathione-agarose beads. After several washes in
lysis buffer, complexes as well as remaining aliquots of untreated
cell lysates were electrophoresedthrough 10% SDS-polyacrylamide
and analyzed by immunoblotting with either anti-EGFR or
anti-PDGFR antibodies (Upstate Biotechnology Inc.) and 'III-
protein A.
Results and Discussion
With thediscoveryofpoint mutations in the PTP1C gene
of both me and me° mice (10), the possibility emerged that
defective function of this hemopoietic tyrosine phosphatase
might underlie expression of the motheaten phenotype. To
confirm the correlation between this phenotype andPTP1C
mutation, the segregation of thenormal and mutant PTP1C
alleles was examined in offspring derived from mating het-
erozygous me and me, mice. For these analyses, a PCR-based
strategy predicated on differential termination of primer ex-
tension (25) was used to distinguish the T-A transversion-
containing me° mutant PTP1C allele from the normal allele;
theseappear as 31- and30-basepair extensionproducts, respec-
tively (Fig. 1 A). The me mutant PTP1C allele was identified
in PCRamplifiedgenomicDNA by taking advantage of the
loss of aTaql restriction site consequent to the C nucleotide
deletion (at position 228) that demarcates this mutant allele
Loss-of-Function Mutations in Motheaten and Viable Motheaten PTP1C GeneFigure 1 .
￿
Detection of the PTP1C
gene mutations in me° and me mice.
(A) A 120-base pair genomic fragment
encompassing the site of the T-A
transversion in the me , PTP1C gene
was PCR amplified from C57BL/6J
me°/+, me°/me°, and +/+ tail DNA
and subjected to two rounds of PCR
primer extension as described in Ma-
terials and Methods. Termination ofex-
tension at the first adenine 3' to the
primer (boxed residues) results in twora-
diolabeled extension products, a 30-
nucleotide (nt) fragment (upper se-
quence) and a 31 nt fragment (lower se-
quence) that represent the me- and
normal PTP1C alleles, respectively . The
radiograph shows the extension prod-
ucts obtained from +/+ (31 nt only),
men/mev (30 nt only) and me~/+ (both
31 and 30 nt) mice . (B)A 118-base pair
genomic fragment encompassing the
site ofthe C deletion (nt position 228)
in the me PTPIC gene was PCR
amplified from tailDNA of parents and
offspring of one C3HeBFeJ me/+ x
mel+ cross asdescribed in Materials and
Methods. PCR products were digested with Taql, electropboresed over a 12% SDS-polyacrylamide gel, and visualized by ethidium bromide staining.
The autoradiograph shows the association of the normal PTP1C allele with two TagI restriction fragments of 53 by and 65 bp, the me PTP1C allele
with an intact 118-bp fragment and the me heterozygous state with all three fragments.
(Fig . 1 B) . The results of segregation analyses using these
two assays (Fig . 1) confirm the presence of point mutations
in the me and me° PTP1C genes and indicate that the
methods permit detection of the PTP1C mutant and normal
alleles and resolution of the me and me heterozygous states.
PTP1C expression was initially examined in normal and
mutant mice by Northern blot analysis and the results
confirmed previous data (12-14) showing expression to be
prominent in hemopoietic tissues (Fig . 2) and negligible in
most other tissues of normal mice (not shown) . The results
also confirm recent data by Shultz et al . (19) showing that
PTP1C RNA expression is comparable in me and normal
bone marrow, but not detectable in me marrow cells (Fig .
2) . Moreover, the data shown in Fig. 2 reveal levels ofPTP1C
transcript to be normal in me° spleen and thymus, while
PTP1C RNA is undetectable in any hemopoietic tissue iso-
lated from me mice. The failure to detect this transcript in
me tissues, in contrast to detection ofapparently normalPTP1C
transcript levels in me° tissues, is consistent with the more
severe nature ofboth the PTP1C mutation and clinical pheno-
type found in me mice.
Analysis of PTP1C protein expression using a polyclonal
anti-PTP1C SH2 domain antibody revealed the presence of
two distinct PTP1C species (N67 and 70 kD, respectively)
in various hemopoietic tissues of both C57BL/6J and
C3HeBFeJ wild type mice (Fig . 3, A and B) . As anticipated
from the analysis of me and me" PTP1C RNA sequences,
neither of these PTP1C molecules were detected in tissues
of me mice (Fig . 3 B), while PTP1C species comparable in
size to wild type PTP1C were apparent in the me° samples
(Fig. 3 A) . However, in contrast to normal mice, the me°
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mice also displayed a lower molecular weight PTP1C species
of about 34 kD . As the 34-kD band was not detected using
an anti-peptide antibody raised against a 14 residue segment
of the PTP1C COOH-terminal tail (not shown), it likely
Figure 2 .
￿
Northern blot analysis of PTP1C expression in me and me°
hemopoietic tissues . Total cellularRNAwas extracted from spleen, thymus,
and bone marrow of C57BL/6J wild type, me, homozygous and me
homozygous mice and 20 Wg samples were electrophoresed over 1% agarose-
formaldehyde gels and transferred to GeneScreen Plus membranes . Mem-
branes were hybridized with a 1-kb PCR amplified fragment from the
PTP1C cDNA (top) and the blots then stripped and reprobed with a 300-
base pair /3-actin gene fragment (bottom) . Positions of the 28S and 18S
rRNAs are shown on the right and the PTP1C and ,Q-actin transcripts
on the left .Figure 3 .
￿
Immunoblot analysis showing PTPIC expression in various
me and me° tissues. Cell lysates were prepared from the indicated tissues
of (A) C57BL/6J wild type and congenic me, heterozygous and homozy-
gous mice and (B) C3HeBFeJ wild type, and congenic me heterozygous
and homozygous mice. 100 Wg of total cell lysate protein was electropho-
resed through SDS-PAGE, transferred to nitrocellulose, and immunoblotted
with rabbit polyclonal anti-PTP1C (A and B) or anti-Syp (C) antibodies
and 1251-protein A . The positions of molecular mass markers are shown
on the right and ofvarious PTP1C species on the left (arrows) . The longer
arrows over the schematic diagram ofPTP1C predicted protein structure
(bottom) indicate the relative positions ofPCR primers used to derive the
PTP1C SH2-domain encoding fragment (amino acids 1-296) that was cloned
into thepGEX expression vector to obtain a GSTPTP1C fusion protein
for derivation of anti-PTPlC SH2 antibodies .
represents a fragment from the NH2-terminal portion of the
protein . Whether this fragment arises by degradation ofone
or both of the me° mutant proteins remains to be deter-
mined, but its presence in me° homozygous and, at a re-
duced level, in me° heterozygous mice, confirms the genetic
data suggesting that me° mutants do not produce normal
PTP1C protein . Similarly, the failure to detect PTP1C in me
tissues using either the anti-carboxy tail peptide (not shown)
or the anti-SH2 domain antibodies, and the detection of about
50% less PTP1C protein in me heterozygous relative to wild
type mice, are consistent with the previous finding ofa frame
shift mutation in the me PTPIC coding region that would
predictably abrogate expression of the protein . By contrast,
the expression of Syp, a ubiquitously expressed cytoplasmic
tyrosine phosphatase structurally similar to PTP1C (16), was
normal in both me and me° mice (Fig. 3 C) . Taken together,
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these results argue for a causal relationship between PTPIC
mutation and expression of the motheaten phenotype.
While previous studies ofPTP1C expression in normal mice
have generally identified only a single 64-68-kD PTP1C spe-
cies (14, 19, 26), the wild type mice studied here clearly ex-
press two distinct PTP1C species (Fig. 3, A and B) . This
latter result is consistent with our previous data showing that
alternative splicing of a 39-amino acid segment within the
PTP1C COOH-terminal SH2 domain results in expression
oftwo distinct PTPIC transcripts in normal bone marrow
(10) . The two isoforms may therefore represent the products
of different PTP1C splice variants. The detection of only a
singlePTPIC species in theC3HeBFeJ wild type thymic cells
studied here (Fig . 3 B) and in the C57BL/6J bone marrow
macrophages studied by Shultz et al . (19), as well as recent
data on PTP1C expression in human tumor cell lines (27),
raise the possibility that PTPIC isoforms may be differen-
tially expressed in various cell types and possibly among
different inbred strains.
PTP1C catalytic activity was also assessed in the mutant
mice and, as anticipated, no anti-PTPlC immunoprecipitable
phosphatase activity was detected in theme spleen cells (Fig.
4 A) . Although in a previous study, some PTP1C catalytic
activity was detected in me macrophages (19), the lack ofany
such activity in the me cells studied here is consistent with
the absence of immunoprecipitable PTP1C protein in these
mice. Similarly, while the amount of protein immunopre-
cipitated from me° spleen cells with anti-PTP1C antibody
appeared comparable to that obtained from normal cells, the
phosphatase activity associated with PTP1C immunoprecip-
itated from me, cells was markedly reduced relative to
PTPIC from normal cells . By comparison, the phosphatase
activities ofthe Syp tyrosine phosphatase immunoprecipitated
from me, me°, and wild type liver, were essentially the same
(Fig. 4 B) . PTP1C protein is therefore not only abnormally
expressed in me and me° hemopoictic cells, but is also dys-
functional in these cells. It is important to note, although
full-length PTP1C polypeptides are expressed in me cells,
these proteins are enzymatically impaired, presumably as a
result of the structural alterations introduced into the phos-
phatase domain by the me° mutation .
To examine the effect of the me and me mutations on
PTP1C SH2 domain function, PTP1C mRNA segments con-
taining the two adjacent SH2 domains were amplified by re-
verse transcriptase (RT)-PCR from me and me° bone
marrow cells and expressed in bacteria as GST fusion pro-
teins. Although the spectrum of proteins interacting with
PTPIC SH2 domains have not been identified, association
of the PTPIC SH2, domain-containing region with activated
EGFR has been demonstrated in vitro (11, 17) . Accordingly,
GST-PTP1C fusion proteins coupled to glutathione-Sepharose
were incubated with cell extracts from EGF-stimulatedR1hER
fibroblasts or PDGF-stimulated Rat-2 cells and the bound
receptors were detected by immunoblotting withanti-EGFR
or anti-PDGFR antibodies, respectively. As shown in Fig.
5, the me° PTP1C SH2 domain fusion protein, which is
identical in sequence to that derived from the wild type PTP1C
SH2 domain segment, associated strongly with the au-
in Motheaten and Viable Motheaten PTP1C GenetophosphorylatedEGFR and PDGFR in this in vitro binding
assay. Similarly, interaction between the me-derived PTP1C
fusion protein and thePDGR expressed in PDGF-stimulated
RAT-2 cells was apparent. By contrast, the me SH2 do-
main-containing fusion protein, which was less than one half
Figure 5 .
￿
AssociationofPTPICSH2 domains with activated EGF and
PDGF receptors. Serum-starvedRat-2 (A) and RIhERfibroblasts (B) were
left unstimulated (-) or stimulated (+) for 5 min with PDGF (A) or
EGF (B) . Aftercold lysis, aliquots ofcell lysateswereincubated withviable
motheaten (SH2 me-Ime°)- and motheaten (SH2 me/me)-derived GST
PTPIC SH2 domain fusion proteins bound to glutathione-agarosebeads.
Complexes as well as remaining aliquots oflysates (cell lwates) were elec-
trophoresed through SDS-PAGE and subjected to immunoblotting with
anti-PDGFR (A) and anti-EGFR (B) antibodies and 1251-protein A. The
positions of molecular mass standards and PDGF and EGF receptors are
indicated .
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Figure 4.
￿
Tyrosine phosphatase activities ofimmuno-
precipitated PTP1C and Syp from normal, me and me°
mice. Celllysates were prepared from spleen (A) and liver
(B) ofme,, me, and congenic wild typemice and 10012g
totalcell lysate protein was immunoprecipitatedwith pro-
tein A-Sepharose beads and anti-PTPICSH2 (A) or anti-
Syp SH2 (B) antibodies as described in Materials and
Methods. Aliquots of the precipitates were electropho-
resed through a 10% SDS-polyacrylamide gel, transferred
to nitrocellulose, and blotted with anti-PTP1C (A) or
anti-Syp (B) antibodies followed by 1251-protein (A) Po-
sitions ofmolecular mass standards are shown onthe right .
Remaining aliquots of the anti-PTP1C (A) and anti-Syp
(B) immunoprecipitates obtained from wild type (" ), me
(A), and me (") tissues were incubated with 2 mM
p-nitrophenyl phosphate at 37°C for varying times and
after addition of NaOH, absorbance was measured at
410 nM as described in Materials and Methods. The results
(upperandlourergraphs on the right) are expressed as percen-
tages relative to the maximum OD 410 urn values ob-
tained in wild type (" ) tissues (i.e., % dephosphorylation) .
the size of the wild type and me SH2 domain fusion pro-
teins (not shown), did not bind to either of these activated
receptors (Fig . 5) . These results provide further evidence that
one or both of the PTPIC SH2 domains can interact with
autophosphorylated forms ofthese receptors, and that PTPIC
function is entirely abrogated by the me mutation .
As suggested by the finding of mutations in the me and
me PTPIC gene and transcripts, the demonstration here
that catalytically active PTP1C is not detectable in me mice
and is greatly diminished in me° mice argues that the
motheaten phenotype results from loss-of-function mutations
in the PTP1C gene. The more significant impairment in
PTP1C tyrosine phosphatase activity seen in me compared
to me° mice provides a biochemical explanation for the
differences in disease severity conferred by these allelic muta-
tions . These findings, in conjunction with the plethora of
hematologic cell defects manifested by me and me mice, in-
dicate that PTP1C is critical to the differentiation of mul-
tiple hemopoietic lineages and imply that other cytoplasmic
tyrosine phosphatases, such as Syp, do not compensate for
the absence of PTP1C catalytic activity in these cells .
The presence inPTPIC oftwo SH2 domain elements sug-
gests that this phosphatase can bind to particular tyrosine
phosphorylated receptors and/or cytoplasmic proteins and that
its influence on hemopoietic cell differentiation and function
may reflect regulatory effects on a subset of signaling pro-
teins. This possibility is supported by data implicating the
structurally similar intracellular tyrosine phosphatase, cork-screw, in the signal transduction pathway elicited by activa-
tion of the Drosophila torso receptor tyrosine kinase (18).
While the specific targets for PTP1C binding and tyrosine
dephosphorylation are unknown, PTP1C can associatewith
activatedEGFR and PDGFR and dephosphorylate theseand
the hER-2-neu (17) receptors in vitro. These observations
maybe ofphysiologic relevance, as epithelial andparticularly
malignant epithelial cells, from which PTP1C was initially
cloned (11), represent themajor nonhemopoietic lineage that
expresses substantial levels of PTP1C. Of more potential
significance in relation to the me phenotype, are recent data
showing that PTP1C dephosphorylates the Kit and CSF-1
receptors in vitro (28) and that tyrosine phosphorylation and
increased expression of PTPIC are induced in conjunction
with phorbol ester-stimulated macrophage differentiation (27)
and CSF-1-stimulated macrophage activation, respectively.
These tyrosine kinase receptors have been implicated in the
induction of early hemopoietic differentiation (29) and de-
velopment and function of mononuclear phagocytes (30),
respectively, and thus a role for PTP1C in regulating signal
transduction pathways activated by these receptors is consis-
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